- IXICO has signed a new contract for specialist imaging clinical trial services.

It said the contract was for a phase II clinical trial of patients with mild cognitive impairment (MCI) due to Alzheimer's disease (AD).

It said the study - sponsored by specialist Spanish biotech company Araclon Biotech, a Grifols company - was designed to establish the dosage regimen for the therapy, as well as confirm the treatment safety and tolerability data obtained in phase I.

Story provided by